As per Health Canada indication: in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Reimburse with clinical criteria and/or conditions
The requested reimbursement criteria are provided by the applicant and do not
the views of CADTH. Reimbursement criteria from CADTH will be documented in the final
recommendation, if applicable.
Call for patient/clinician input open
Call for patient/clinician input closed
- Patient input submission received from Lung Cancer Canada and Lung Health Foundation
Draft CADTH review report(s) provided to sponsor for comment
Deadline for sponsors comments
CADTH responses on draft review report(s) provided to sponsor
Expert committee meeting (initial)
Draft recommendation issued to sponsor
Draft recommendation posted for stakeholder feedback
End of feedback period
Final recommendation issued to sponsor and drug plans
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)